

The Role of Biostatistics in Immunogenicity Testing

Gopi Shankar, Ph.D., MBA
Senior Director, Biologics Clinical Pharmacology

Feb 24, 2014

Janssen Research & Development, LLC

ONE TEAM Making the Difference for Patients WORLDWIDE



Lisbon 2014 - February 24-26

Sixth Open Scientific EIP Symposium
Immunogenicity of Biopharmaceuticals

ADA detection methods – common issues

- Qualitative; there is no reference standard.
- Require a “cut-point”.
- *ADA is not “an analyte”; it is a spectrum of analyte/reactivity*
 - Species specific
 - Epitope specific
 - polyclonal (probably), varying avidities
 - In humans, ADA could be expressed as IgG1, IgG2, IgG3, IgG4, IgM, IgA, IgE; Other species produce other isotypes
- Assay development depends upon availability of analyte (a positive control)
Assay performance is optimized for THE positive control analyte on hand; we are lucky when more than one positive control is available. Defines assay sensitivity and drug tolerance.
- So how good is a test method based on a single analyte, in detecting “a spectrum of analyte” in the subjects?

The Challenges We Face...

- *Statistics for Qualitative assays? Are you crazy or just being mean?* 😊
- Anti-drug antibodies can impact safety. Assay results are relevant to clinical outcomes. *So, we need to be conservative...*
- Tiered ADA testing scheme for practical reasons: Screen-negative samples are not tested anymore. *So, we need to be conservative...*
- ADA assays don't just produce +/- results. They produce a continuum of signal, of which non-specific binding ("background") must be differentiated from specific binding
- Some drug naive patients, and also some healthy volunteers, have high reactivity in the ADA assay. Is that non-specific, pre-existing ADA, or a specifically binding interferent (false-positive for ADA)?
- Pre-existing antibodies versus treatment emergent antibodies

For all these reasons, we must make our best effort to reduce subjectivity & increase objectivity

How did we do it before any of the consensus publications and regulatory guidance documents?

1. Variable and subjective approaches to screening cut point


- a. No false-positive rate built-in
- b. LLOQ or LLOD approach
- c. Based on low positive control value
- d. Drug and ADA naive sera, but using 2SD or 3 SD
- e. Without eliminating outliers
- f. Without eliminating true-reactive samples (pre-existing antibodies)
- g. Etc.

2. Specificity confirmation cut point *

- a. No competitive inhibition approach used. Dilution or titration, or orthogonal assay, used to confirm
- b. Competitive inhibition using positive control
- c. Etc.

The 2000's – Biotech's *Immunogenicity Decade*

Adapted from Dr. Ronald Bowsher's presentation



ADA Immunoassay Development

2004



Journal of Immunological Methods 289 (2004) 1–16



Standardization

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

Anthony R. Mire-Sluis^{a,*}, Yu Chen Barrett^b, Viswanath Devanarayan^c, Eugen Koren^d, Hank Liu^e, Mauricio Maia^f, Thomas Parish^g, George Scott^h, Gopi Shankarⁱ, Elizabeth Shores^j, Steven J. Swanson^d, Gary Taniguchi^{k,l}, Daniel Wierda^l, Linda A. Zuckerman^m

KEY MESSAGES:

- ADA immunoassays qualitative (screening) or quasi-quantitative (titration)
- Assay quality controls: positive and negative controls should be used
 - When possible, polyclonal antibody positive controls are preferred
 - Depending on the assay type, species-specific assays should preferably have species specific controls
- Use a risk-based approach to assure that low positive samples can be identified, and false-negative samples are limited. The screening assay cut point should be computed to allow (theoretically) the selection of of 5% false-positive samples
- Immunoassay sensitivity: clinical – 250 to 500 n/mL; non-clinical – 500 to 1000 ng/ml

ADA Immunoassay Validation

2008



Contents lists available at ScienceDirect

Journal of Pharmaceutical and Biomedical Analysis

journal homepage: www.elsevier.com/locate/jpba



Review

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

Gopi Shankar^a, Viswanath Devanarayan^b, Lakshmi Amaravadi^c, Yu Chen Barrett^d, Ronald Bowsher^e, Deborah Finco-Kent^f, Michele Fiscella^g, Boris Gorovits^h, Susan Kirschner^{i,1}, Michael Moxness^j, Thomas Parish^k, Valerie Quarmby^l, Holly Smith^m, Wendell Smithⁿ, Linda A. Zuckerman^o, Eugen Koren^{p,*}

KEY MESSAGES:

- *Objective decision criteria are critical; subjective approaches should be eliminated/minimized*
- *Alternate objective approaches may also be applied*
- *Application of statistics is important (balanced experimental design, outlier exclusion, etc)*
- *Assay means and variability across runs drives choice of screening assay cut point: fixed, floating or dynamic*
- *Specificity cut point should be based on analytical and biological variation (like screening cut point)*
- Positive controls used to validate methods may not represent the analyte (ADA)
- CAUTION: over-reliance or dependence on quantitative data (sensitivity, drug tolerance) generated using positive control "standard" reagents

Assay performance characteristics for validation

Where is a statistical approach critical?

1. Screening cut point*
2. Specificity confirmation cut point*
3. Titer cut point
4. Sensitivity
5. Interference
 - Drug tolerance
 - Target tolerance
6. System suitability control ("QC") criteria*
7. Precision*
8. Robustness
9. Stability

Final Remarks

- To ensure objective criteria, use of statistics is important
- The analyses need not be complicated; can do without an expert statistician, where possible
- But let's see what our statistician friends have to say today...